LoginSignup
immagine del profilo
SemiGrowth
@SemiGrowth
1Anno·

$MEDP (-3,88%) Were earnings really that bad? Sales are supposed to be lower, but the bottom line has been raised considerably and the backlog has also grown.

Billings have collapsed, which is probably the reason, but I see a good long-term entry point

2
17 Commenti
immagine del profilo
Tenbagger2024@Tenbagger2024
1Anno
As far as I know, there are figures on Wednesday.
It is often the case that some investors sell before the figures and get nervous.
Let's wait and see on Wednesday.
At the moment I think the whole market is pretty nervous.
•
2
•
immagine del profilo
SemiGrowth@SemiGrowth
1Anno
@Tenbagger2024 Haven't the figures already come out?
•
1
•
immagine del profilo
Tenbagger2024@Tenbagger2024
1Anno
••
immagine del profilo
Dennis@GordonGekko83
1Anno
@Tenbagger2024 numbers are out!
•
2
•
immagine del profilo
Brody@Brody
1Anno
@Tenbagger2024 Do you have an idea? Sell on good news? At first glance, it can't be the figures.
••
immagine del profilo
Brody@Brody
1Anno
••
Utente eliminato
1Anno
Il commento è stato cancellato
immagine del profilo
SemiGrowth@SemiGrowth
1Anno
@Memo0606 am now in for the long term. I don't think the valuation is too high. MEDP is virtually a shovel manufacturer in an important sector of the future
••
Utente eliminato
1Anno
Il commento è stato cancellato
immagine del profilo
SemiGrowth@SemiGrowth
1Anno
@Memo0606 I've just added it to my watchlist, but haven't gotten around to it yet
••
Utente eliminato
1Anno
Il commento è stato cancellato
immagine del profilo
SemiGrowth@SemiGrowth
1Anno
@Memo0606 I just had a look at it, it looks great. I think I'll go in there sometime
••
Utente eliminato
1Anno
Il commento è stato cancellato
immagine del profilo
SemiGrowth@SemiGrowth
1Anno
@Memo0606 fantastic margins (80 Gross, >30 Net, >20 FCF), favorable in historical comparison. The product positioning in the high-margin segments (animals, cancer) and especially the latter is likely to be a growth market. At the moment, everyone is only looking at Eli Lilly, which is why this could be an anti-cyclical play in the sector. I like how the management handles cash (conservative). Only the relatively high level of debt is a negative point. Sales growth is currently low. But profit and FCF growth is extremely high (due to base effects). The valuation of 13 P/E is quite favorable in my opinion. Oh and Merck is also a long-term runner, compounder or quality stock with a discount
••
Utente eliminato
1Anno
Il commento è stato cancellato
immagine del profilo
SemiGrowth@SemiGrowth
1Anno
@Memo0606 I will probably go in in installments, but I don't know when yet.

You can consider a momentum discount strategy against the "runaway". For example, you buy when it rises/falls above 108 or below 101. Then you either have a low price and if it doesn't fall that low, you're still in. Or you go in in very small tranches. Then you at least have a few shares should it run away from you
•
1
•
Visualizza un'altra risposta
Partecipa alla conversazione
IscrivitiAccesso